Idiopathic Pulmonary Fibrosis Treatment Market Projected to Reach USD 7.81 Billion by 2034, Growing at a 6.9% CAGR

𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭-𝐌𝐚𝐫𝐤𝐞𝐭 Insights, Size Revenue, Outlook, Overview, and Analysis. The idiopathic pulmonary fibrosis treatment market was estimated to be worth USD 4.01 billion in 2024 and is predicted to expand to USD 7.81 billion by 2034, with a CAGR of 6.9% from 2025 to 2034.

𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐜𝐨𝐩𝐞:
This comprehensive study provides an accurate overview of the worldwide idiopathic pulmonary fibrosis treatment market. Comprehensive analyses of sales volume, price, revenue, market share, and important companies are included. The market is further divided into segments by drug class, route of administration, distribution channel, and region in the study, which offers a comprehensive picture of the state of the market.

𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/request-for-sample

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧:
Idiopathic pulmonary fibrosis (IPF) is a type of interstitial pneumonia characterized by progressive and irreversible lung fibrosis. The condition is defined by the development of scar tissue in the lungs, beginning at the edges and moving towards the center, resulting in breathing complications and inadequate oxygen supply to the body's tissues. Diagnosis involves chest imaging, lung biopsies, pulmonary function tests, and antibody tests. Two popular antifibrotic treatments are medications based on nintedanib and pirfenidone, which enhance lung function and reduce the chances of acute respiratory decline. They are commonly used with oxygen therapy and palliative care to offer comfort and enhance the patient's recovery.

𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐓𝐫𝐞𝐧𝐝𝐬:
• Older people are at higher risk of developing pulmonary fibrosis because they lose protective stem cells and pericytes as they age, which can cause fibroblast activation and growth. As the world's population gets older, the number of cases of idiopathic pulmonary fibrosis rises.
• Improvements in diagnostic techniques are greatly contributing to the expansion of the idiopathic pulmonary fibrosis (IPF) treatment market. Enhanced imaging methods like high-resolution computed tomography (HRCT) allow for the earlier and more precise identification of IPF, making timely treatment easier.

𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬:
The market is marked by fierce competition, and the leading companies rely on innovative technology, superior goods, and a strong brand identity to boost sales.
Here are the top companies in the idiopathic pulmonary fibrosis treatment market:
• F. Hoffmann-La Roche Ltd
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Medicinova, Inc
• Merck & Co., Inc.
• Galapagos NV
• Novartis AG
• Fibrogen, Inc.
• Avalyn Pharma Inc.
• Promedior, Inc.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/request-for-discount-pricing

𝐂𝐨𝐮𝐧𝐭𝐫𝐲-𝐖𝐢𝐬𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
According to regional analysis, North America held the largest revenue share in 2024 because of its advanced healthcare system, effective healthcare regulations and emphasis on research and development are also driving growth in the market in North America.
Also, during the projection period, Asia Pacific is projected to register a significant CAGR because of the increasing occurrence of idiopathic pulmonary fibrosis; increasing knowledge and improved diagnostic techniques are anticipated to drive market expansion in Asia Pacific throughout the forecast period.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤:
𝐁𝐲 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟐𝟎-𝟐𝟎𝟑𝟒)
• Pirfenidone
• Nintedanib
• Interferon Gammato1b
• Others

𝐁𝐲 𝐑𝐨𝐮𝐭𝐞 𝐨𝐟 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟐𝟎-𝟐𝟎𝟑𝟒)
• Oral
• Injectable
• Others

𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟐𝟎-𝟐𝟎𝟑𝟒)
• Hospital Pharmacies
• Retail Pharmacies
• Others

𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟐𝟎-𝟐𝟎𝟑𝟒)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/inquire-before-buying

𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬
• Based on route of administration, the oral segment is anticipated to register a significant CAGR in the global market during the forecast period. This growth is attributed to its several advantages, including ease of use and potential of outpatient management.
• By distribution channel, the hospital pharmacies segment accounted for the largest revenue share of the market in 2024 due to increasing hospitalization rates and the availability of specialized care for patients requiring advanced treatments.
• In 2024, North America accounted for the largest revenue share of the global idiopathic pulmonary fibrosis treatment market due to its advanced medical infrastructure
• The idiopathic pulmonary fibrosis treatment market in India is projected for significant growth during the forecast period due to the increased investments in its pharmaceutical manufacturing sector.
• A few global key market players are F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Medicinova, Inc; Merck & Co., Inc.; Galapagos NV; Novartis AG; and Fibrogen, Inc.

𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭:
𝐓𝐞𝐥𝐞𝐫𝐚𝐝𝐢𝐨𝐥𝐨𝐠𝐲 𝐒𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/teleradiology-software-market

𝐍𝐞𝐞𝐝𝐥𝐞 𝐇𝐨𝐥𝐝𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/needle-holder-market

𝐒𝐭𝐞𝐫𝐢𝐥𝐞 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/sterile-injectable-contract-manufacturing-market

𝐂𝐞𝐥𝐥 𝐏𝐫𝐨𝐜𝐞𝐬𝐬𝐢𝐧𝐠 𝐈𝐧𝐬𝐭𝐫𝐮𝐦𝐞𝐧𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/cell-processing-instruments-market

𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐗-𝐑𝐚𝐲 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/digital-x-ray-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.